Literature DB >> 22758394

Role of CD44 in tumour progression and strategies for targeting.

Lalit Mohan Negi1, Sushama Talegaonkar, Manu Jaggi, Farhan J Ahmad, Zeenat Iqbal, Roop K Khar.   

Abstract

CD44 or hyaluronan receptor is a transmembrane receptor associated with aggressive tumour growth, proliferation, and metastasis. In normal physiology, this receptor has a crucial role in cell adhesion, inflammation, and repair processes. However, many tumour cells over-express this receptor and abuse it to become progressive and perpetual units. The article comments from common functioning of the CD44 receptor, to its diabolic multi-dimensional effects in promotion of malignant cells. It also illuminates the relations of CD44 endorsed processes with other biomolecular events in cancer progression. In an end, the review focuses comprehensively at ongoing researches to exploit the CD44 over-expression as a probable target in treatment, management, and diagnosis of malignancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22758394     DOI: 10.3109/1061186X.2012.702767

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  38 in total

Review 1.  Therapies targeting cancer stem cells: Current trends and future challenges.

Authors:  Denisa L Dragu; Laura G Necula; Coralia Bleotu; Carmen C Diaconu; Mihaela Chivu-Economescu
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

Review 2.  Cancer stem cell marker glycosylation: Nature, function and significance.

Authors:  Brody W Mallard; Joe Tiralongo
Journal:  Glycoconj J       Date:  2017-06-17       Impact factor: 2.916

3.  Advancing chemical risk assessment decision-making with population variability data: challenges and opportunities.

Authors:  Weihsueh A Chiu; Ivan Rusyn
Journal:  Mamm Genome       Date:  2018-01-03       Impact factor: 2.957

4.  CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.

Authors:  Elena Sanmartín; Fernando Ortiz-Martínez; Eloy Pomares-Navarro; Araceli García-Martínez; Montserrat Rodrigo-Baños; Marta García-Escolano; Leire Andrés; Enrique Lerma; Francisco I Aranda; Pascual Martínez-Peinado; José M Sempere-Ortells; Gloria Peiró
Journal:  Virchows Arch       Date:  2016-11-24       Impact factor: 4.064

5.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

6.  Deguelin inhibits the migration and invasion of lung cancer A549 and H460 cells via regulating actin cytoskeleton rearrangement.

Authors:  Honggang Zhao; Yan Jiao; Zuncheng Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

7.  Role of CD44 as a marker of cancer stem cells in head and neck cancer.

Authors:  Serena Trapasso; Eugenia Allegra
Journal:  Biologics       Date:  2012-11-01

8.  A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.

Authors:  K L Simpson; C Cawthorne; C Zhou; C L Hodgkinson; M J Walker; F Trapani; M Kadirvel; G Brown; M J Dawson; M MacFarlane; K J Williams; A D Whetton; C Dive
Journal:  Cell Death Dis       Date:  2013-05-02       Impact factor: 8.469

9.  Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells.

Authors:  Silvia Arpicco; Giuseppe De Rosa; Elias Fattal
Journal:  J Drug Deliv       Date:  2013-03-07

10.  Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum.

Authors:  Masae Naruse; Koji Shibasaki; Shuichi Yokoyama; Masashi Kurachi; Yasuki Ishizaki
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.